3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
4
Breast Neoplasms
3
Melanoma
2
Colorectal Neoplasms
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Resectable Localized Prostate Cancer
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Liver Neoplasms
1
Klatskin Tumor
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Glioma
1
Gastrointestinal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
44
Gemcitabine
23
enfortumab vedotin
21
Nivolumab
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Hydroxychloroquine
×
1 year
×
Clear all
No trials found.